Reuters examines how the experimental Merck/Moderna cancer vaccine functions and outlines the key scientific, logistical, and economic hurdles preventing its widespread clinical deployment.

Moderna's stock fell by 7% as traders booked profits following a significant year-to-date surge, with BioNTech and Merck also experiencing declines. In contrast, Tracsis stock saw a notable surge in its value.

This article highlights significant analyst calls made during the week, featuring Apple, Merck, and Analog Devices among the top stock picks.

Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

Moderna and Merck have reported a significant breakthrough in cancer vaccines, particularly for melanoma, which could lead to a new wave of treatments. The market reaction to Moderna's melanoma results has been noted as contrary to expectations.

Moderna and Merck have announced a significant breakthrough in their mRNA-based cancer vaccine, which has shown promising results in curbing melanoma, with Moderna's chairman discussing the development.

Several major stocks, including Broadcom (AVGO), Merck (MRK), Hewlett Packard Enterprise (HPE), and Alibaba (BABA), saw analyst upgrades and downgrades on Thursday. These revisions influenced market movements and investor sentiment.

Jim Cramer outlined his top 10 market watchpoints for Thursday, noting Walmart's sell-off due to disappointing earnings and divided analyst opinions on Merck following its cancer vaccine breakthrough.

Merck's stock has been a subject of debate regarding its valuation, with analysts questioning if it remains undervalued despite an 80% surge and significant success with its cancer vaccine, following a recent downgrade due to perceived stretched valuation.

Moderna, Merck, Micron, Marvell, Estée Lauder, and Honeywell Aerospace are among the stocks highlighted as significant drivers of today's market movements.

Merck and Moderna announced that their collaborative cancer vaccine has shown promising signs in preventing the recurrence of melanoma in patients.

Moderna and Merck have announced a breakthrough in personalized cancer vaccines, with their melanoma vaccine succeeding in a large trial. Separately, the Faecal Immunochemical Test (FIT) has been hailed as a 'game changer' in the fight against colorectal cancer in western Jamaica.

A cycling tour through Flanders explores the region's history, where the Zwin estuary once brought immense wealth to Bruges before silting up, bringing its lost ports back to life.

New analyst reports have been published, providing detailed insights and evaluations for both Merck & Co Inc and AutoNation Inc. These reports offer financial analysis and recommendations for the respective companies.

An analysis compares Pfizer and Merck as dividend investment options following their respective second-quarter earnings reports, evaluating which company presents a smarter dividend play.

Merck KGaA, a German science and technology company, has raised its financial outlook, citing robust demand for its lab tools and products used in chip manufacturing.

Merck's stock increased as Wall Street investors prioritized the company's strong oncology performance over a cut in its earnings guidance.

The HHS secretary is under scrutiny for a potential conflict of interest after giving his stake in a lawsuit against Merck to his son, with his department later settling with the company.

Hipgnosis founder and former CEO Merck Mercuriadis, who recently launched a new venture, is slated to deliver a keynote address at the Music Tectonics Conference in Santa Monica, California, in October 2026.

An article delves into the underlying reasons behind Merck stock's premium valuation, exploring the factors that contribute to its high price.

Drugmaker Merck has announced that its new cholesterol-fighting drug, Lipfendra, has received FDA approval. The medication can be used in conjunction with or as an alternative to statins.

This article provides an earnings preview, outlining key expectations and factors to consider ahead of Merck & Co.'s upcoming financial report.

Several stocks, including AeroVironment, Strategy, and Merck, are experiencing significant movement in premarket trading. Some stocks are notably gapping down before the market opens.

German pharmaceutical and chemical company Merck has announced an $11.3 billion deal to acquire Bio-Techne, significantly boosting its life sciences business. This acquisition aims to strengthen Merck's position in the biotechnology sector.

Merck's acquisition of Bio-Techne has brought the Life Sciences sector into focus, highlighting top quant-rated stocks in the industry.

German pharmaceutical and life science company Merck has reached an agreement to acquire Bio-Techne in a deal valued at $11.3 billion, expanding its portfolio in the biotechnology sector.

Merck (MRK) stock has been given a new 'Outperform' rating by CICC, indicating a positive outlook from the investment bank.

Merck has received European Union approval for its Keytruda and Padcev combination therapy for the treatment of bladder cancer.

An article discusses Merck's recently revealed $50 billion plan and its potential impact on the company's stock performance and future outlook.

Cancer drugmaker Revolution Medicines announced that a sale is not a priority, pushing back against acquisition attempts. This statement follows an unsuccessful $32 billion bid from Merck, indicating the biotech company's intent to remain independent.

Pharmaceutical giant Merck has inked a deal with Protillion for AI-driven drug discovery, with the potential value of the agreement reaching up to $510 million.

Pharmaceutical companies Merck and Gilead have reported positive outcomes from their Phase 3 clinical trials for a new combination pill designed to treat HIV.

An investment analysis compares Pfizer and Merck, examining their potential for high yield versus higher overall returns for investors.

Merck & Co. (MRK) has announced its quarterly dividend payment to shareholders. This is a routine corporate financial update for the pharmaceutical giant.

Several companies, including IMAX, Merck, and Estee Lauder, are experiencing significant stock movements in premarket trading.

The Merck Foundation has recognized former First Lady Lordina Dramani Mahama as its Ambassador, celebrating her decade of humanitarian contributions through the Lordina Foundation.

Merck announced that its experimental drug, Sac-TMT, successfully met both primary endpoints in its Phase 3 clinical trial for endometrial cancer. This marks a significant step forward in the drug's development.

Merck (MRK) reported quarterly sales that surpassed forecasts, primarily attributed to the strong performance and growth of its blockbuster drug Keytruda.

Inquirer.net data journalist Cristina Eloisa Baclig won the grand prize in the online category of the 2025 Merck Foundation Media Recognition Awards for her reporting on health issues affecting Filipinos.

Merck & Co. has chosen Salesforce AI CRM to develop a comprehensive 360-degree animal health platform.

Tempus AI is projecting revenues between $1.59 billion and $1.6 billion and approximately $65 million in adjusted EBITDA by 2026, supported by its collaboration with Merck.

An analysis explores the factors that make Merck & Co. (MRK) a potential investment opportunity.

This week's notable healthcare headlines focus on key industry players such as Merck, Eli Lilly, and GE HealthCare.

Merck & Co. Inc. is highlighted as one of the top low-risk, high-growth stocks for investors to consider buying at the moment.

Jim Cramer expressed his strong approval for Merck, calling the pharmaceutical company "Terrific."

A financial analysis article examines Wall Street's recommendation to buy Merck over Pfizer, delving into the underlying numbers to present a more nuanced perspective on their stock performance.

Merck & Co., Inc. (MRK) has been granted FDA Priority Review for its KEYTRUDA regimen in the treatment of muscle-invasive bladder cancer.

Pharmaceutical company Merck has secured approval for its new HIV drug regimen, Idvynso, marking a significant development in HIV treatment options.

The Merck Foundation and Kenya's First Lady launched their 'Educating Linda' program at Kenya State House, aimed at supporting girl education.

A recent Merck Youth Barometer survey indicates that 16-20 year olds, particularly young men, favor traditional gender roles where men work and women care for children, while young women advocate for equal roles.

Merck's stock experienced gains, breaking a six-day period of losses in the market.

Pharmaceutical giant Merck is undergoing a transformation driven by strategic acquisitions as it prepares for the upcoming patent expiration of its top-selling cancer drug, Keytruda.

Pharmaceutical giant Merck's stock is reportedly forming a bullish chart pattern, indicating a potential for a significant price jump within the health-care sector.

Pharmaceutical giant Merck & Co (MRK) announced strong financial results for its fourth quarter, leading to a positive market reaction.

Merck (MRK) has announced strong Phase 3 clinical trial results for its oral PCSK9 inhibitor, a drug designed to lower cholesterol.

A late-stage trial of a new Merck drug demonstrated a reduction in bad cholesterol by up to 64.6%, meeting its main goal in a head-to-head trial.

Merck (MRK) shares have risen considerably following financial commentator Jim Cramer's advice to investors to 'stay the course' with the company.

Pharmaceutical giant Merck & Co. has announced its intention to acquire Terns Pharma for $6.7 billion, touting the 'best-in-class' potential of TERN-701 for Chronic Myeloid Leukemia (CML) as a key driver for the deal.

RBC Capital Markets has reiterated its 'Outperform' rating for Merck (MRK), acknowledging investor concerns regarding a 'modest premium' but maintaining a positive outlook for the pharmaceutical company.

Merck has finalized its acquisition of Terns Pharmaceuticals for nearly $6 billion to boost its cancer drug pipeline, though analysts and investors are now questioning the premium paid for the deal.

Merck has finalized a deal worth nearly $6 billion to acquire Terns, a cancer biotech company, signaling a major acquisition in the pharmaceutical and biotechnology sector.

Slovenian cycling champion Tadej Pogačar delivered an exceptional performance to secure his maiden victory in the first monument of the season, earning praise from Eddy Merckx.

Merck (MRK) saw a significant surge in its stock performance during the fourth quarter, driven by undisclosed factors.

Investment analysts have raised their price targets for Merck shares after clinical data demonstrated promising efficacy for the company's oncology pipeline, boosting investor confidence.

Merck and Moderna announced that a personalized cancer vaccine showed promise in preventing the return and spread of melanoma in a large trial involving over 1,000 patients, offering new hope for cancer patients.

Merck's stock has been downgraded despite a significant win with its cancer vaccine, as analysts note a stretched valuation and a strong but potentially overvalued pipeline. This comes after a period of positive news for the pharmaceutical company.

Elon Musk expressed optimism about mRNA technology's potential after Moderna and Merck announced a cancer vaccine breakthrough. Following the news, MRNA stock experienced a significant drop of over 11% in premarket trading.

Merck's stock experienced a rally after a checklist related to the company was published in advance.

This report summarizes the leading Wall Street analyst research calls for Thursday, covering various companies including Alphabet, Analog Devices, Crown Castle, Ebay, and Merck & Co., among others.

An analysis compares the performance of leading drugmaker stocks, including Merck, Pfizer, and Amgen, to determine which has dominated in 2026.

An analysis provides recommendations on whether to buy, sell, or hold stocks for pharmaceutical giants Eli Lilly, Novo Nordisk, and Merck.

This week's notable healthcare headlines highlight developments concerning companies such as Eli Lilly, Hims & Hers Health, and Merck.

A potential partnership between Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD) is being explored as a possible new engine for growth in the pharmaceutical industry.

Yahoo Finance provides an overview of analyst estimates and ratings for Merck & Co's stock.

Merck & Co., Inc. held its Q2 earnings call, highlighting key financial results and business updates for the quarter.

Bristol Myers Squibb (BMS) has been granted FDA review for a label expansion of its anemia therapy, developed in partnership with Merck.

With high hopes for a new HIV prevention pill, pharmaceutical company Merck is taking steps to ensure global access, including allowing companies in Africa and India to produce generic versions that could significantly lower costs.

Merck's share price has seen a boost following the introduction of a new cholesterol pill and positive earnings growth.

Merck's new cholesterol therapy, Lipfendra, has received FDA approval in the United States. The once-daily oral PCSK9 inhibitor is described as 'game-changing,' shown to reduce LDL cholesterol by approximately 56% to 60% when combined with statins.

Pfizer has received FDA label expansion for its drug Padcev when used in combination with Merck’s Keytruda for the treatment of bladder cancer.

Notable healthcare headlines for the week put Merck, AbbVie, and Bayer in focus, indicating significant developments within these pharmaceutical companies.

Bio-Techne (TECH) shares surged 20% following news of a potential $11.3 billion merger with Merck, indicating a positive market reaction to the deal.

German pharmaceutical giant Merck KGaA is expanding its life science footprint by acquiring US-based lab equipment supplier Bio-Techne for approximately $11.3 billion (9.9 billion Euros).

Merck KGaA, the German science and healthcare firm, has announced an agreement to acquire biotech company Bio-Techne for $11.3 billion.

An article discusses whether Merck & Co., Inc. (MRK) is strengthening its vaccine portfolio with the recent approval of its new Capvaxive vaccine.

Financial analysis provides strategies on how to potentially buy Merck stock for a 10% discount or achieve an 11% annual return.

Merck is expanding its kidney cancer treatment portfolio by leveraging its drugs KEYTRUDA and WELIREG.

Merck has received a U.S. label expansion for its Capvaxive pneumococcal shot, broadening its approved uses.

Merck announced that its drug Welireg has received an FDA label expansion, allowing its use in treating kidney cancer.

An analysis explores whether Merck & Co. (MRK) is considered one of the best cheap stocks for beginner investors.

A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer recurrence or death by nearly half.

Merck (MRK) has announced a notes offering as a strategic move to strengthen its capital structure and enhance financial stability.

Summit's stock has been downgraded by H.C. Wainwright after the release of new data from Merck regarding its sac-TMT treatment.

Pfizer has won a trademark dispute against Merck in Singapore concerning a vaccine brand, securing its intellectual property rights.

Merck announced that its new cancer drug, sac-TMT, has demonstrated strong results in phase 3 trials. The drug offers new hope for patients battling advanced or recurrent aggressive endometrial cancers.

Regeneron's Libtayo combination therapy has encountered a late-stage trial setback in its competition against Merck's Keytruda.

Merck has raised its annual forecast, driven by strong demand in its lab materials and equipment business for drug development, as well as high demand for semiconductors.

Erasca announced a collaboration with Merck to test its drug ERAS-0015 in combination with Keytruda, causing a significant increase in Erasca's share price.

New analyst reports have been published, providing detailed insights and evaluations for a diverse group of major companies across various sectors. These reports offer financial analysis and outlooks for firms including Waste Management, Chevron, and Merck & Co.

The stele depicting Belgian cycling legend Eddy Merckx in Woluwe-Saint-Pierre, Brussels, has been vandalized, with his face reportedly torn off, according to local authorities.

An analysis suggests Merck stock appears undervalued, citing the growth of its drug KEYTRUDA and a strong pipeline as factors offsetting near-term headwinds.

The Zacks Analyst Blog has published several posts highlighting various companies across different sectors. These analyses cover firms such as Cullen/Frost Bankers, Sonic Automotive, Moderna, Merck, Apple, Amazon, and Starbucks.

Merck & Co., Inc. released highlights from its first-quarter earnings call, providing insights into its financial and pharmaceutical developments.

Merck posted a quarterly loss primarily due to a charge related to Cidara, even as its sales rose by 5%.

CNN provides an analysis of the stock quote, current price, and future forecast for MRK (Merck & Co.). This report offers insights into the company's market performance.

An analysis explores whether pharmaceutical giant Merck & Co. (MRK) is a favorable investment choice during a bear market, evaluating its resilience and potential for growth.

Merck's proposed acquisition of Terns Therapeutics has successfully passed the expiration of the Hart-Scott-Rodino (HSR) antitrust waiting period, moving the deal closer to completion.

Pharmaceutical companies Merck and Eisai have encountered a setback in a late-stage clinical trial for their Keytruda regimen, intended for the treatment of kidney cancer.

Pfizer and Astellas have received FDA priority review for their bladder cancer treatment, Padcev, when used in combination with Merck's Keytruda, signaling a potential expedited approval process for the therapy.

An article compares Novartis and Merck to determine which pharmaceutical company offers a better dividend stock option for investors.

An analysis suggests a bullish diagonal trade for Merck (MRK) stock, targeting a price of $130 by June 18.

A joint investigation by DW and ICIJ highlights how pricing and patent strategies have made Merck's Keytruda a top-selling drug while limiting access for many patients worldwide. The report uncovers a significant global divide in the availability of the life-saving medicine.

An earnings preview for Merck & Co.'s upcoming quarterly report has been released, offering insights into what investors can expect from the pharmaceutical giant.

This article analyzes whether defensive stocks like Costco and Merck are currently overbought, prompting investors to consider if it's too late to buy them.

Merck & Co. (MRK) is being highlighted as a top affordable stock choice, praised for its robust earnings growth potential.

Merck's oral PCSK9 enlicitide has shown improved cholesterol-lowering capabilities when compared to non-statin treatments.

Merck Life Science has inaugurated an AI-powered chemistry lab at KAIST, strengthening its partnership with Korea’s leading science and technology university.

Merck, the pharmaceutical giant, continues to view China as a crucial and vital base within its global business operations and strategy, reaffirming its commitment to the country.

Pharmaceutical giant Merck has reached an agreement for a deal valued at nearly $6 billion to acquire Terns, a biotechnology company focused on cancer research.

Citi has increased its price target for Merck & Co. (MRK) to $125 from $120.

Pharmaceutical giant Merck has reached an agreement to acquire cancer biotech company Terns in a deal valued at nearly $6 billion, expanding its portfolio in oncology.

An investment analysis evaluating whether Merck & Co., Inc. (MRK) is a good stock to buy now.

This week's notable healthcare headlines focus on developments concerning Moderna, Merck, and Twist Bioscience, highlighting key updates in the sector.

Scientists are hopeful about a new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc., which has shown success in preventing melanoma from returning and could usher in a new era of cancer vaccines. This development brings researchers closer to using vaccines to train the immune system to destroy cancer cells.

A new mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. continues to show promise in preventing melanoma recurrence, with a recent breakthrough suggesting it could usher in a new era of cancer vaccines.

The article examines Merck & Company's investment in Evaxion A/S and its implications for validating the potential of artificial intelligence in vaccine discovery.

Moderna and Merck & Co. have reported positive study results for a new cancer therapy, marking a potential significant advance in cancer treatment and drawing attention to the implications for vaccine skeptics.

Merck has been upgraded by Morgan Stanley following a successful cancer trial, with analysts citing a strong cancer drug pipeline. However, RBC has downgraded the company, indicating differing perspectives on its future.

Needham reiterated a 'Buy' rating for Bill.com stock with a $75 target following its results, while Citizens reiterated its rating for NexPoint Residential stock, citing swap headwinds. These analyst reports provide updated perspectives on the companies' financial outlooks.

A significant and unusual volume of put options in Merck (MRK) stock has been observed, prompting questions about whether the company's shares might be overvalued.

Moderna and Merck announced that their melanoma therapy met its primary goal in a Phase 3 trial, leading to significant jumps in both companies' stock prices. Moderna's shares rocketed 93%, while Merck's rose 7% following the positive news.

Merck Executive Vice President (EVP) DeLuca has sold $5.9 million worth of company stock.

A summary of Wednesday's top Wall Street analyst research calls includes updates on companies such as The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, and Okta.

Veronesi's novel 'Septiembre negro' is set in 1972 on the beaches of Tuscany, weaving a narrative that involves terrorists and cycling legend Eddy Merckx, adapting evocative imagery to its structure and rhythms.

Merck's application to expand the U.S. label for its RSV shot, Enflonsia, has been accepted by the FDA for review, potentially broadening its use.

Merck & Co., Inc. published its Q2 2026 earnings call summary, reporting on its financial performance and business updates for the second quarter.

Several prominent stocks, including McDonald's, Caterpillar, Palantir, and Merck, are experiencing significant movements in premarket trading. This report highlights the companies making the biggest shifts before the market opens.

A complaint has been filed against pharmaceutical company Merck, alleging that its selective drug distribution practices are creating access problems for patients undergoing in vitro fertilization (IVF) treatments.

The FDA has approved Merck's once-daily cholesterol pill Lipfendra (enlicitide), marking the first oral PCSK9 inhibitor.

Personalis, a genomics company, is said to have attracted takeover interest from pharmaceutical giant Merck.

Merck's new cholesterol pill has received approval from the U.S. Food and Drug Administration (FDA). This powerful new medication is expected to offer a significant treatment option for patients.

A House committee has launched an investigation into several pharmaceutical companies, including Eli Lilly, Bristol, Merck, and AbbVie, regarding their clinical trials in China, particularly those tied to military-linked hospitals and facilities in Xinjiang, citing biotech risks.

Merck KGaA is reportedly set to acquire Bio-Techne in a deal valued at $11.3 billion.

Bio-Techne's stock experienced a significant surge after Merck KGaA announced a cash acquisition offer of $73 per share, signaling a major development in the biotechnology sector.

Merck KGaA has announced plans to acquire Bio-Techne for $11.3 billion, a move aimed at expanding its footprint in the life science sector.

Acquisition of US medical tools maker will be German group’s biggest in over a decade

Analysts on Wall Street have issued their top research calls for Wednesday, covering a range of companies including Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, and Twilio.

IDA Ireland is actively targeting new investors to fill the economic void created by the shutdown of Merck's facility in Arklow.

A weekly roundup highlights significant developments in the healthcare sector, focusing on key updates from pharmaceutical companies Merck, Moderna, and Biogen.

Merck (MRK) and Keurig Dr Pepper (KDP) have been highlighted as top undervalued counter-cyclical stocks to consider buying. Both companies are presented as strong investment opportunities in the current market.

Merck Animal Health has announced its intention to acquire TARGAN, a developer of biodevices. This acquisition is expected to expand Merck's portfolio and capabilities within the animal health technology sector.

Merck's Curiosity Cube, a mobile science laboratory, visited Arklow to provide hands-on STEM experiments and educational experiences to the local community.

A new mRNA melanoma vaccine developed by Merck and Moderna has demonstrated sustained benefits over five years, significantly reducing the risk of cancer recurrence or death by almost half in trials.

Moderna and Merck have released encouraging data from their collaborative efforts on an mRNA-based cancer vaccine, generating optimism in the medical community.

Merck announced that its Phase 3 TroFuse-005 trial, investigating a treatment for endometrial cancer, successfully met its primary endpoints, marking a significant development in oncology.

A combination therapy for lung cancer developed by Merck and Kelun has demonstrated better results than Keytruda in a late-stage clinical trial.

A combination therapy for lung cancer developed by Kelun and Merck demonstrated improved survival rates in a late-stage clinical trial conducted in China.

Merck Foundation, the philanthropic arm of Merck KGaA Germany, has honoured First Lady Lordina Mahama as its Ambassador in recognition of the impact she has made over the past decade through her…

Merck Life Science and GC Biopharma have signed a strategic memorandum of understanding to expand cooperation in biopharmaceutical development, good manufacturing practice production processes, and technical collaboration.

An analyst has reinstated coverage of Merck (MRK) with a 'Neutral' rating and set a price target of $125.

The Merck Foundation announced 124 winners from 32 countries for its 'More Than a Mother' and 'Diabetes and Hypertension' Media Awards 2025.

An analyst has raised Merck's price target by $1 after the pharmaceutical company surpassed its first-quarter earnings estimates.

A summary of the top research calls from Wall Street analysts for various companies, including Advanced Micro Devices, American Eagle Outfitters, and Palantir Technologies, was released on Wednesday.

Jim Cramer commented on Merck & Co.'s stock performance, observing that the stock is beginning to recover.

This article discusses the sentiment of Wall Street analysts regarding Merck & Co. stock, examining their recommendations and outlook for the company's performance.

Qatar Science & Technology Park (QSTP), in collaboration with Merck, has officially launched a new FemTech Accelerator program, attracting significant global interest from founders.

After five years at the helm of Merck, Belén Garijo is stepping down to take on the role of CEO at the French pharmaceutical company Sanofi. This move marks a significant career change for Garijo, who will be taking on a challenging new leadership position.

Belén Garijo, the CEO of Merck, is stepping down from her position, having been the first woman to reach the top leadership role in a DAX-listed company.

Infinimmune and Merck (MRK) have entered into an agreement focused on antibody discovery.

Merck (MRK) is highlighted as one of the top counter-cyclical stocks available for purchase. The analysis details why the pharmaceutical company's stock is considered a strong investment choice, particularly in uncertain economic times.

Pharmaceutical giant Merck and other rival companies are reportedly showing interest in acquiring Inhibrx's cancer drug, signaling potential major developments in the oncology market.

Pharmaceutical manufacturers are facing a potential helium shortage, with current supplies lasting only four to eight weeks, due to disruptions related to the Strait of Hormuz. While Merck does not anticipate immediate bottlenecks, Boehringer is seeking to reduce its reliance on helium imports.

Merck has significantly impacted the funding landscape for vaginal drug delivery, addressing a previous lack of investment in the area.

UBS has increased its price forecast for Merck (MRK) as part of its broader sector preview, indicating a positive outlook for the pharmaceutical giant.

Nevena Vidaković, General Manager and Executive Director of Merck Bulgaria, discusses the factors shaping the future of family-oriented work environments. She shares insights from her extensive career and international experience.

Concerns are rising in India over the cancer drug Keytruda's availability, high cost, and reports of leaks and fake versions. Merck & Co has stated that healthcare facilities are responsible for the used packaging of the drug.

Merck & Co. (MRK) is being evaluated as one of the best consistent dividend stocks available for purchase. This assessment focuses on its reliability for income-seeking investors.

Infinimmune and Merck have entered into a new collaboration agreement focused on antibody discovery. This pact aims to advance research and development in the field of immunology.

Merck Pill Lowers Cholesterol by 64% in Study, Rivaling Shots  Bloomberg.com

This article highlights notable healthcare headlines for the week, focusing on developments related to companies such as Merck, Medtronic, and Novartis.

Jim Cramer suggests that Merck & Co. is likely to be an outperformer if the economy enters a slowdown triggered by an oil shock.

Merck has announced a $6.7 billion deal to acquire a leukemia treatment, a strategic move as the company prepares for the upcoming expiration of exclusivity for its blockbuster cancer drug, Keytruda.

Merck has reached an agreement to acquire cancer biotech firm Terns in a deal valued at nearly $6 billion, expanding its portfolio in the oncology sector.

Merck is looking to forge deeper collaborations within China's pharmaceutical innovation sector, aiming to expand its presence and contributions to the market.